Literature DB >> 11356716

Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor.

S Petersenn1, A C Rasch, M Penshorn, F U Beil, H M Schulte.   

Abstract

Synthetic GH secretagogues stimulate GH release through binding to a recently cloned specific GH secretagogue receptor (GHS-R). The endogenous ligand of this receptor may be part of a new endocrine pathway controlling GH secretion. Two different receptor variants, type 1a and 1b, have been described that differ in their 3'-terminal amino acids. We investigated the genomic structure and transcriptional regulation of the human GHS-R. An 18-kb genomic clone including sequences encoding for the two GHS-R variants was isolated. Sequencing revealed that the two variants originate from specific RNA processing of a single gene that spans approximately 4.1 kb. The transcription start site was defined by 5'-inverse PCR analysis at position -227. RT-PCR analysis points to differential transcriptional initiation and processing. Type 1a is encoded by two exons; 2152 bp of intronic sequence are removed by splicing at position 796/797 relative to the translation start site. Type 1b is encoded by a single exon. A putative polyadenylation signal consensus motif was identified at position +4118; 2.7 kb of the 5'-flanking region were sequenced, and putative transcription factor binding sites were identified. Transcriptional regulation was investigated by transient transfections using promoter fragments ranging in size from 168-1745 bp; 1745 bp of the GHS-R promoter directed significant levels of luciferase expression in GH(4) rat pituitary cells, whereas no activity was detected in monkey kidney COS-7 cells, human endometrium Skut-1B cells, mouse hypothalamic LHRH neuronal GT1-7 cells, or mouse corticotroph pituitary AtT20 cells. A minimal 309-bp promoter allowed pituitary-specific expression. Its activity in COS-7 cells was enhanced by cotransfection of the pituitary-specific transcription factor Pit-1. We did not find any regulation of the GHS-R promoter by forskolin, somatostatin, insulin-like growth factor I, or 12-O-tetraphorbol 12-myristate 13-acetate. Thyroid hormone and estrogen lead to a significant stimulation; glucocorticoids lead to a significant inhibition. Further mapping suggests a thyroid hormone-responsive element, an estrogen-responsive element, and a glucocorticoid-responsive element located between -309 and the translation start codon. These studies demonstrate the nature of the human GHS-R gene and identify its 5'-flanking region. Furthermore, pituitary-specific activity of the promoter and regulation by various hormones are demonstrated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356716     DOI: 10.1210/endo.142.6.8184

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  29 in total

1.  Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis.

Authors:  S O Nascif; M H Senger; J C Ramos-Dias; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

2.  Genetic linkage and association of the growth hormone secretagogue receptor (ghrelin receptor) gene in human obesity.

Authors:  Andrea Baessler; Michael J Hasinoff; Marcus Fischer; Wibke Reinhard; Gabriele E Sonnenberg; Michael Olivier; Jeanette Erdmann; Heribert Schunkert; Angela Doering; Howard J Jacob; Anthony G Comuzzie; Ahmed H Kissebah; Anne E Kwitek
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

3.  Melatonin regulates somatotrope and lactotrope function through common and distinct signaling pathways in cultured primary pituitary cells from female primates.

Authors:  Alejandro Ibáñez-Costa; José Córdoba-Chacón; Manuel D Gahete; Rhonda D Kineman; Justo P Castaño; Raúl M Luque
Journal:  Endocrinology       Date:  2014-12-29       Impact factor: 4.736

4.  Gender, sex-steroid, and secretagogue-selective recovery from growth hormone-induced feedback in older women and men.

Authors:  Johannes D Veldhuis; Dana Erickson; Jean Wigham; Sue Weist; John M Miles; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2011-05-25       Impact factor: 5.958

5.  Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Authors:  Silvia Regina Correa-Silva; Sérgio Oliva Nascif; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

6.  Ghrelin in the human myometrium.

Authors:  Margaret O'Brien; Padraig Earley; John J Morrison; Terry J Smith
Journal:  Reprod Biol Endocrinol       Date:  2010-05-28       Impact factor: 5.211

7.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

8.  Differential pulsatile secretagogue control of GH secretion in healthy men.

Authors:  Catalina Norman; John Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

9.  Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.

Authors:  Johannes D Veldhuis; Kristi L Mielke; Mihaela Cosma; Cacia Soares-Welch; Remberto Paulo; John M Miles; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

10.  Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis.

Authors:  Sergio Oliva Nascif; Patrícia Molica; Silvia Regina Correa-Silva; Marcos Roberto Silva; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2009-04-26       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.